AstraZeneca (AZN) Given a GBX 4,080 Price Target at Goldman Sachs Group

Goldman Sachs Group set a GBX 4,080 ($53.15) price target on AstraZeneca (LON:AZN) in a research report released on Wednesday. The brokerage currently has a sell rating on the biopharmaceutical company’s stock.

AZN has been the subject of several other research reports. Citigroup reissued a buy rating on shares of AstraZeneca in a research note on Thursday, June 28th. UBS Group reissued a neutral rating and issued a GBX 5,900 ($76.85) price target on shares of AstraZeneca in a research note on Tuesday. Credit Suisse Group set a GBX 5,900 ($76.85) price target on shares of AstraZeneca and gave the company a buy rating in a research note on Friday, July 27th. Shore Capital reissued a hold rating on shares of AstraZeneca in a research note on Monday. Finally, Barclays reissued an overweight rating on shares of AstraZeneca in a research note on Monday. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of GBX 5,689.45 ($74.11).

Shares of LON AZN opened at GBX 5,918 ($77.09) on Wednesday. AstraZeneca has a 12-month low of GBX 4,260 ($55.49) and a 12-month high of GBX 5,520 ($71.90).

The firm also recently disclosed a dividend, which was paid on Monday, September 10th. Shareholders of record on Thursday, August 9th were given a dividend of GBX 68.40 ($0.89) per share. This represents a yield of 1.19%. The ex-dividend date was Thursday, August 9th.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: How to Use a Moving Average for Trading 

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply